



It is made available under a CC-BY 4.0 International license.



- 59 *Background*
- 60 To evaluate the utility of polygenic risk scores (PRS) in identifying high-risk individuals, different
- 61 publicly available PRS for breast (n=65), prostate (n=26), colorectal (n=12) and lung cancers (n=7)
- 62 were examined in a prospective study of 21,694 Chinese adults.
- 63
- 64 *Methods*
- 65 We constructed PRS using weights curated in the online PGS Catalog. PRS performance was
- 66 evaluated by distribution, discrimination, predictive ability, and calibration. Hazard ratios (HR) and
- 67 corresponding confidence intervals [CI] of the common cancers after 20 years of follow-up were
- 68 estimated using Cox proportional hazard models for different levels of PRS.
- 69
- 70 *Results*
- 71 A total of 495 breast, 308 prostate, 332 female-colorectal, 409 male-colorectal, 181 female-lung and
- 72 381 male-lung incident cancers were identified. The area under receiver operating characteristic curve
- 73 for the best performing site-specific PRS were 0.61 (PGS000004, breast), 0.66 (PGS00586, prostate),
- 74 0.58 (PGS000148, female-colorectal), 0.60 (PGS000734, male-colorectal) and 0.55 (PGS000740,
- 75 female-lung), and 0.55 (PGS000392, male-lung), respectively. Compared to the middle quintile,

76 individuals in the highest PRS quintile were 67% more likely to develop cancers of the breast,

- 77 prostate, and colorectal. For lung cancer, the lowest PRS quintile was associated with 31-45%
- 78 decreased risk compared to the middle quintile. In contrast, the hazard ratios observed for quintiles 4
- 79 (female-lung: 0.91 [0.58-1.44]; male-lung: 1.01 [0.74-1.38]) and 5 (female-lung: 1.00 [0.64-1.56];
- 80 male-lung: 1.07 [0.79-1.45]) were not significantly different from that for the middle quintile.
- 81
- 82 *Conclusions*
- 83 Site-specific PRSs can stratify the risk of developing breast, prostate, and colorectal cancers in this
- 84 East Asian population. Appropriate correction factors may be required to improve calibration.
- 85
- 86 *Funding*

It is made available under a CC-BY 4.0 International license.

- 87 This work is supported by the National Research Foundation Singapore (NRF-NRFF2017-02),
- 88 PRECISION Health Research, Singapore (PRECISE) and the Agency for Science, Technology and
- 89 Research (A\*STAR). WP Koh was supported by National Medical Research Council, Singapore
- 90 (NMRC/CSA/0055/2013). CC Khor was supported by National Research Foundation Singapore (NRF-
- 91 NRFI2018-01). Rajkumar Dorajoo received a grant from the Agency for Science, Technology and
- 92 Research Career Development Award (A\*STAR CDA 202D8090), and from Ministry of Health
- 93 Healthy Longevity Catalyst Award (HLCA20Jan-0022).
- 94 The Singapore Chinese Health Study was supported by grants from the National Medical Research
- 95 Council, Singapore (NMRC/CIRG/1456/2016) and the U.S. National Institutes of Health [NIH] (R01
- 96 CA144034 and UM1 CA182876).
- 97

## 98 **Keywords**

99 Population-based cancer screening, polygenic risk score, cohort study, Asian, calibration

It is made available under a CC-BY 4.0 International license.

## 101 **INTRODUCTION**

102 Polygenic risk scores (PRS) for a range of health traits and conditions have been developed 103 in recent years. These scores, which are based on summary statistics from genome-wide association 104 studies (GWAS), can be used to stratify people depending on their genetic risk of acquiring various 105 diseases, to improve screening and preventative interventions, as well as patient care [1, 2]. Precision 106 risk assessment may help develop tailored screening strategies targeting individuals at higher risk of 107 disease of interest [3].

108

109 The contributions of heritable genetic factors are different for different cancers. Twin studies 110 have highlighted statistically significant effects of heritable genetic risk factors for cancers of the 111 prostate, colorectal, and breast [4]. The amount of phenotypic variance explained by the common 112 genetic variants found by GWAS is also known to vary [5], suggesting that PRS derived from GWAS 113 findings may perform to varying degrees for different cancers.

114

115 The area under receiver operating characteristic curve (AUC) is an important discrimination 116 index for evaluating the performance of PRS. The greater the AUC, the better the discriminatory 117 ability to separate cases from non-cases. A value of 0.5 suggests that the tool is performing no better 118 than chance, while a value of 1 is obtained when cases and non-cases are perfectly separated. The 119 range of reported AUC associated with published PRS ranged from 0.584 to 0.678 for breast cancer 120 [6-12], 0.591 to 0.769 for prostate cancer [8, 10, 13], 0.609 to 0.708 for colorectal cancer [8, 10, 14, 121 15], and 0.52 to 0.846 for lung cancer [8, 10, 13, 16]. In a study by Jia et al looking at eight common 122 cancers in the UK Biobank population-based cohort study (n=400,812 participants of European 123 descent), the observed AUC ranged from 0.567 to 0.662 [10].

124

125 While prediction of individual cancer risks through PRS remains moderate, emerging data 126 supports the use of PRS for population-based cancer risk stratification. In previous work, Ho et al 127 examined the overlap of women identified to be at high risk of developing breast cancer based on 128 family history for the disease, a non-genetic breast cancer risk prediction model, a breast cancer PRS, 129 and carriership of rare pathogenic variants in established breast cancer predisposition genes [17]. The 130 overlap of individuals found to be at elevated risk of developing breast cancer based on the genetic

It is made available under a CC-BY 4.0 International license.



It is made available under a CC-BY 4.0 International license.

#### 161 *Baseline*

162 An in-person baseline interview was performed at recruitment to collect data on diet using a 163 validated 165-item food frequency questionnaire, smoking, alcohol, physical activity, medical history, 164 and menstrual and reproductive history from women.

165

166 *Selection of common cancers* 

167 In Singapore, between 2015 and 2019, colorectal cancer, the most prevalent cancer in men, 168 accounted for nearly 17% of cancer diagnoses, while breast cancer, the most common cancer in 169 women, accounted for about three out of ten cancer diagnoses (Singapore Cancer Registry Annual 170 Report 2018). During this time, cancers of the breast, prostate, colorectal, and lung accounted for 171 approximately half of the total cancer diagnoses. These four most common cancers were selected for 172 inclusion in this study.

173 A unique National Registration Identity Card (NRIC) number for every Singaporean enables 174 the compilation and linkage of data from national register data to the same individual [20].

175 Identification of incident cases of cancer was accomplished by record linkage of all surviving cohort

176 participants with the database of the nationwide Singapore Cancer Registry [20]. Cancers that

177 developed among SCHS participants were identified using International Classification of Diseases

178 (ICD) codes ICD-O-3 (breast: C50, prostate: C61, colorectal: C18, C19 and C20, lung: C34).

179

180 *Follow-up* 

181 Death date was obtained by record linkage with the database Birth and Death Registry of 182 Singapore [20]. To date, only 47 (<1%) of the entire cohort participants were known to be lost to 183 follow-up due to migration out of Singapore, suggesting that the ascertainment of cancer and death 184 incidences among the cohort participants was virtually complete.

185

#### 186 **Genotyping and imputation**

187 Between 1999 and 2004, a total of 28,346 subjects contributed blood samples. A total of

188 25,273 SCHS participants were genotyped between the years 2017 to 2018 with the Illumina Infinium

189 Global Screening Array (GSA) v1.0 and v2.0 [21].

It is made available under a CC-BY 4.0 International license.



200 Alleles for all SNPs were coded to the forward strand and mapped to hg19. SNP quality 201 control steps included the exclusion of sex-linked and mitochondrial variants, gross Hardy–Weinberg 202 equilibrium (HWE) outliers (P < 1 x 10<sup>-6</sup>), monomorphic SNPs or those with a minor allele frequency 203 (MAF) < 1.0%, and SNPs with low call-rates (<95.0%). We imputed for additional autosomal SNPs 204 using IMPUTE v2 [22] and with a two reference panel imputation approach by including 1) the 205 cosmopolitan 1000 Genomes reference panels (Phase 3, representing 2,504 samples) and 2) an 206 Asian panel comprising 4,810 Singaporeans ( 2,780 Chinese, 903 Malays, 1127 Indians) [21]. SNPs 207 with imputation quality score INFO < 0.8, MAF < 1.0%, or HWE P < 1  $\times$  10<sup>-6</sup>, as well as non-biallelic

208 SNPs were excluded.

## 209 **Polygenic risk scores (PRS)**

210 Published polygenic risk scores (PRS) were retrieved from The Polygenic Score (PGS) 211 Catalog, an open database of polygenic scores (retrieved on Feb 26, 2022) (**Additional file 1 -**  212 **Supplementary Table 1**) [23]. Of the 2,166 PRS available in the resource, 1,706 PRS comprising 213 less than 100,000 predictors were downloaded. A total of 65, 26, 12, and 7 PRS were available for 214 breast, prostate, colorectal, and lung cancers, respectively. **Additional file 1 - Supplementary Table**  215 **2** shows the number of individual variants comprising each PRS and proportion of variants missing in 216 the SCHS cohort. Individual PRS were calculated using the allelic scoring (–score sum) functions with 217 default parameters in PLINK (v1.90b5.2) [24].

218

It is made available under a CC-BY 4.0 International license.

#### 219 **PRS distribution**

- 220 Two-sided, two-sample t-tests with a type I error of 0.05 were used to examine whether there 221 was a difference in the distribution of standardised PRS (subtraction of mean value followed by the 222 division by the standard deviation) between site-specific cancer cases and non-cancer controls.
- 223

## 224 **PRS discrimination**

- 225 Discrimination was quantified by the area under the receiver operating characteristic (ROC)
- 226 curve (AUC), using logistic regression models, and their corresponding 95% CI. An AUC of 0.9–1.0 is
- 227 considered excellent, 0.8–0.9 very good, 0.7–0.8 good, 0.6–0.7 sufficient, and 0.5–0.6 insufficient
- 228 [25].
- 229

# 230 **Associations between PRS and risk of developing cancers**

231 Subjects were classified into PRS percentile groups. Person-years of follow-up were 232 calculated for each subject from the date of enrolment to the date of cancer diagnosis, death, or 233 December 31, 2015 (the date of linkage with the Singapore Cancer Registry), whichever came first. 234 Follow-up time was censored at 20 years after recruitment. The associations between PRS quintiles 235 (where individuals ranked by PRS were categorised into quintiles, using the middle quintile [40 to 236 60%] as reference to reflect the average risk of the population) and the incidence of site-specific 237 cancers were investigated using Cox proportional hazards modelling to estimate hazard ratios (HR) 238 and corresponding 95% confidence intervals (CI), using time since recruitment as the time scale, and 239 adjusted for age at recruitment. Tests for trends were conducted using two-sided Wald tests with a 240 type I error of 0.05. Assumptions for proportional hazards were checked using the cox.zph() function 241 in the "survival" package in R.

242

243 HR and corresponding 95% CI were also estimated for every standard deviation (SD) 244 increase in PRS. Variables adjusted in the models included age at recruitment, dialect group (Hokkien 245 or Cantonese), highest level of education (no formal education, primary school, or secondary or 246 higher), body mass index (continuous,  $kg/m<sup>2</sup>$ ), cigarette smoking (non-smoker, ex-smoker, current 247 smoker), alcohol consumption (never, weekly, daily), moderate physical activity (none, 1-3h/week,

It is made available under a CC-BY 4.0 International license.

248 ≥3h/week), vigorous work/strenuous physical activity at least once a week (no or yes), and familial

249 history of cancer (no or yes).



It is made available under a CC-BY 4.0 International license. medRxiv preprint doi: [https://doi.org/10.1101/2022.09.12.22279874;](https://doi.org/10.1101/2022.09.12.22279874) this version posted September 15, 2022. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grant

278 was 54 years (interquartile range [IQR]: 49 to 61). The median age at diagnosis was 65 years (IQR: 279 59-70) for female breast cancers, 72 years (IQR: 67 to 77) for prostate cancers, 71 years (IQR: 65 to 280 76) for male colorectal cancers, 71 years (IQR: 64 to 78) for female colorectal cancers, 74 years (IQR: 281 68 to 78) for male lung cancers and 74 years (IQR: 66 to 79) for female lung cancers. Sixteen percent 282 of the cohort (n=3,501) reported positive first-degree family history of any cancer at baseline 283 interview. 284 285 Overall, eight in ten participants (79%) reported an education level of primary school and 286 above. However, the proportion of females who did not receive an education (32%) was four times 287 higher compared to males (8%). Median BMI was 23 kg/m<sup>2</sup> in the overall cohort, as well as in sex 288 specific and site-specific subgroups. There were more non-smokers among females (93%) compared 289 to males (45%). Alcohol consumption was low among the participants, with 88% of the cohort 290 reported never or occasional drinking (79% male, 95% female). Three in four participants reported 291 regular engagement in moderate physical activity; 85% of the participants reported no participation in 292 higher levels of physical activity. 293 294 **Lack of Asian representation in PRS development**  295 Among PRS for breast (n=65), prostate (n=26), colorectal (n=12) and lung cancers (n=7) 296 examined, the reported source of variant associations or GWAS used to build PRS were from 297 predominantly European ancestry populations (**Additional file 1 - Supplementary Table 2**). Only one 298 PRS for breast cancer (PGS001778) and two PRS for colorectal cancer (PGS000802 and 299 PGS000734) were based on GWAS that included some non-European participants. For PRS 300 development training, all but two PRS were based on samples of non-European ancestry 301 (PGS000733 for prostate cancer and PGS000802 for colorectal cancer). No significant association 302 (P>0.05) was found between number of variants included in the various PRS evaluated for each 303 cancer and discriminatory ability (**Additional file 1 - Supplementary Table 3**). 304 305 **PRS distribution**  306 **Figure 1** depicts the A) distribution, B) discrimination, C) predictive ability, and D) calibration 307 of the best-performing PRS (based on AUC) (**Additional file 1 - Supplementary table 3**) for the four

It is made available under a CC-BY 4.0 International license.

308 cancers studied: breast (PGS000004), prostate (PGS00586), colorectal (female: PGS000148; male: 309 PGS000734), and lung (female: PGS000740; male: PGS000392). All PRS were normally distributed, 310 with a right shift observed in the distribution curves for cancer cases (**Figure 1A**). The mean value of 311 each site-specific cancer PRS was significantly higher in cancer patients compared to controls  $(P_t)$ 312 test<0.00273). 313 314 **Associations between PRS and risk of developing cancers**

315 During the follow-up period of 20 years, the risk of acquiring breast, colorectal, or lung cancer 316 increased significantly with higher PRS after adjusting for age at recruitment. Compared to the first

317 PRS quintile, individuals in the highest quintile were more likely to develop the four cancers studied.

318 The highest hazard ratio observed was for prostate cancer (4.72 [95%CI: 3.04 – 7.34]) and lowest for

319 male lung cancer (1.54 [1.10 – 2.16]), adjusted for age at recruitment (**Additional file 1 -**

320 **Supplementary Table 4**). Significant trends were found for the associations between PRS quintiles

321 and site-specific cancers (P-trend ranges from  $7.30 \times 10^{-17}$  for prostate cancer to 0.029 for female lung

322 cancer, **Additional file 1 - Supplementary Table 4**).

323

324 Compared to the middle PRS quintile, individuals in the highest PRS quintile were more than 325 67% more likely to develop cancers of the breast, prostate, and colorectal (**Table 2**). Individuals in the 326 lowest PRS quintile were associated with a 30-65% reduction in risk of developing these cancers. For 327 lung cancer, the lowest PRS quintile was associated with 31-45% decreased risk compared to the 328 middle quintile. However, the hazard ratios observed for quintiles 4 (female: 0.91 [0.58 to 1.44]; male: 329 1.01 [0.74 to 1.38]) and 5 (female: 1.00 [0.64 to 1.56]; male: 1.07 [0.79 to 1.45]) were not significantly 330 different when compared to the middle quintile.

331

332 Every SD increase in PRS is associated with 35-73% elevated risks of breast, prostate and 333 colorectal cancers (P<2.19  $\times$  10<sup>-7</sup>, **Table 3**). The increased risk for female and male lung cancer was 334 lower than the other three cancers (HR<sub>female</sub>: 1.17 [1.01 to 1.36], p=4.07 x 10<sup>-2</sup>; HR<sub>male</sub>: 1.17 [1.06 to 335  $\,$  1.29], p=1.52 x 10<sup>-3</sup>). Age at recruitment is significantly associated with elevated risks of developing all 336 cancers, with the exception of female breast cancer (HR: 1.00 [0.99 to 1.02], p=0.571). Highest 337 education level and BMI were positively correlated with breast cancer risk. Smoking was significantly

It is made available under a CC-BY 4.0 International license.

338 associated with a ~30% reduction in risk of prostate cancer, but increased the risk of lung cancer by 339 approximately two- and five-fold for past and current smokers, compared to non-smokers, 340 respectively. Alcohol consumption increased the risk of both female and male colorectal cancer by 341 approximately 60% but was only significant for male colorectal cancer. Family history of cancer was 342 only significantly associated with an increased risk for prostate cancer (HR: 1.61 [1.22 to 2.13], 343  $p=7.59 \times 10^{-4}$ ). 344 345 **Number of cancers that developed within PRS at-risk groups**  346 Modelling (Cox proportional hazards) the risk of developing cancer using standardized PRS 347 and accounting for age at recruitment, 14-23% of participants were at a greater than 1.5 risk of 348 developing prostate (23%), female breast (14%) and male colorectal cancer (14%) (**Table 4**). The 349 proportions were lower for female colorectal (6%) and lung cancer (1%). The number of participants 350 who developed site-specific cancers in the at-risk group represented 42%, 25%, 22%, 11%, and 1% 351 for prostate, female breast, male colorectal, female colorectal, and lung cancers, respectively. Among 352 1,674 women who were associated with HR>1.5 based on per standard deviation increase of PRS, 353 115 breast cancers (6.9%) developed during the follow-up. This proportion is nearly twice that of 354 women not identified to be at high risk (380/10,410, 3.7%). Among 2,220 men who were associated 355 with HR>1.5 based on per standard deviation increase of PRS, 120 prostate cancers (5.4%) 356 developed during the follow-up. This proportion is over twice that of men not identified to be at high 357 risk (118/7,390, 2.5%). 358 359 When age at recruitment was included in the models, 14-44% of the participants were at a 360 greater than 1.5 risk of developing the various cancers. The number of participants who developed 361 site-specific cancers in the at-risk group increased to 24-55%. In the fully adjusted models, 18-58% 362 the participants were at a greater than 1.5 risk of developing the various cancers. The number of

363 participants who developed site-specific cancers in the at-risk group increased further to 32-74%.

364

365 All Cox models presented in **Tables 2, 3** and **4** did not violate the proportionality assumption 366 for the PRS studied (p-values of *cox-zph()* for PRS were >0.05).

367

It is made available under a CC-BY 4.0 International license.

## 368 **PRS discriminatory ability**

- 369 The highest AUC obtained from logistic models was observed for prostate cancer (0.66, 95%
- 370 CI: [0.62 to 0.69]), followed by female breast cancer (0.61 [0.58 to 0.63]), male colorectal cancer
- 371 (0.60, 95% CI = 0.58 to 0.63), female colorectal cancer (0.58 [0.54 to 0.61]), male lung cancer (0.55
- 372 [0.52 to 0.58]) and female lung cancer (0.55 [0.50 to 0.59]) (**Figure 1B**).
- 373

#### 374 **PRS predictive ability**

- 375 In terms of the five-year absolute risk of developing site-specific cancers, the largest
- 376 difference between the highest and lowest PRS categories was observed for prostate cancer,
- 377 followed by breast cancer (**Figure 1C**). A separation of the absolute risk curves was observed for
- 378 female breast cancer already at age 30 years. For prostate cancer, the separation of curves was
- 379 observed only after age 50 years. Slight separation of the curves began after 50 years of age for
- 380 colorectal and lung cancer.

381

## 382 **PRS calibration**

383 In general, predicted risks for the higher PRS categories did not correspond well to the 384 observed proportions for female breast, prostate, and female lung cancers (**Figure 1D**); in particular, 385 predicted risks were overestimated for the higher risk categories. Overestimation of risk was observed 386 for all PRS categories for male lung cancer. In contrast, predicted risks were underestimated for both 387 female and male colorectal cancers.

388

## 389 **DISCUSSION**

390

391 Precision prevention in oncology is based on the idea that an individual's risk, which is 392 influenced by genetics, environment, and lifestyle factors, is linked to the amount of benefit achieved 393 through cancer screening [28]. Risk stratification for cancer screening can be used in this framework 394 to identify and recommend screening for persons with a high enough cancer risk that the benefits 395 outweigh the risks. Several PRS prediction models have been established for site-specific cancers, 396 each with its own set of strengths and limitations, and different risk models may produce different 397 results for the same individual.

It is made available under a CC-BY 4.0 International license.

398 In an increasingly inclusive world, genetic studies fall short on diversity. According to a 2009 399 study, an overwhelming 96% of people who took part in genome-wide association studies (GWAS) 400 were of European ancestry [29]. GWAS results are the backbone on which PRS is developed. A 401 concern raised was that, without representation from a broader spectrum of populations, genomic 402 medicine may be limited to benefitting "a privileged few" [30].

403

404 Genetic studies in 2016 showed that the proportion of people not of European ancestry 405 included in GWAS has increased to approximately 20% [30]. Most of this rise can be attributed to 406 more research on Asian ancestry communities in Asia [30]. With increasing interest worldwide in 407 using a risk-based approach to screening programs over the current age-based paradigm, this 408 progress raises questions on whether selected established PRS shown to perform well in European-409 based populations has equal utility in Asians. Nonetheless, as our results show, most of the 410 populations from which PRS were developed are still predominantly of European ancestry.

411

412 In accordance with published Polygenic Risk Score Reporting Standards, we reported PRS 413 distribution, discrimination, predictive ability, and calibration for each of the four common cancers 414 studied [31]. Our results show that cancer cases were associated with higher PRS compared to non-415 cancer controls. In the age-adjusted models, a constant trend between PRS percentile rank and 416 observed cancer risk in our study population supports the validity of PRS for breast, prostate, and 417 colorectal cancers, but not for lung cancer. The best-performing PRS for female breast cancer was 418 able to stratify women into distinct bands of breast cancer risk at an earlier age, and across all ages, 419 suggesting that it could be a useful prediction tool in risk-based breast cancer screening in 420 combination with other risk factors specific to breast cancer [17]. This PRS has been incorporated into 421 a pilot risk-based breast cancer screening study in a comparable study population [32]. The best 422 performing PRS for prostate and male colorectal cancers in this study appeared to exhibit sufficient 423 discriminatory ability and predictive value, especially for older participants.

424

425 PRS may be of limited use in predicting female colorectal and female/male lung cancer. The 426 least predictive value was in lung cancer, which could be related to the higher prevalence of EGFR 427 mutant lung cancer which has an Asian predilection, thus less amenable to PRS developed in

It is made available under a CC-BY 4.0 International license.

428 Caucasian population [33]. For these patients <10% of population were identified with >1.5 HR of 429 developing incident cancers.

430

431 There is room for improvement in the discriminatory ability of PRS [34]. As noted by Lambert 432 et al in a review, a wider divergence between the average scores of cases and non-cases (quantified 433 by AUC) and associated effect sizes (odds ratio and standard deviation) is expected when PRS 434 explains more of the heredity for each trait [2]. Larger GWAS sample sizes of appropriate ancestries 435 and the inclusion of rarer genetic variants, obtained through other methods such as whole-genome 436 sequencing, would likely be required to boost explained heritability [2]. In addition, group-wise 437 estimates, which arbitrarily classify the top 10%, 5%, or 1% of samples as the at-risk group, are not 438 optimal for decisions at the individual level [34]. Emerging new methodologies that estimate 439 probability values for hypothetically assigning an individual as at risk or not at risk, thus providing 440 individuals with more clarity, may help to overcome this limitation [35]. At this point, PRS may not 441 have yet reached the standards as a clinical tool by itself. However, it is still helpful in guiding 442 screening decisions and supplementing established protocols [1].

443

444 As highlighted by Wei et al, the reliability of score values is necessary for application at the 445 individual level [36]. Even when the PRS have adequate discrimination, estimated risks can be 446 unreliable [37]. Our results show that cancer risk estimates based on PRS developed using 447 populations of European ancestry are not optimally calibrated for our Asian study population. Poorly 448 calibrated PRS can be misleading and have clinical repercussions [37, 38]. Underestimation of risk 449 may result in a false sense of security. Overestimation of risk may cause unnecessary anxiety, 450 misguided interventions, and overtreatment. In a population-wide screening setting, however, where 451 the return of PRS results can be designed such that only high-risk individuals are highlighted, 452 underestimation of risk may be less of an issue. Arguably, with parallel input from other risk factors 453 and evaluation by healthcare specialists, the overestimation of risk that results in a higher number of 454 at-risk individuals identified may increase the number of cancers potentially detected early. 455 Nonetheless, suitable correction factors will be required to ensure the reliability of PRS prior to clinical 456 implementation.

457

It is made available under a CC-BY 4.0 International license.

458 While the study population used in this analysis comprises less than a thousand cases of the 459 most common cancers examined, the Singapore Chinese Health Study, established between April 460 1993 and December 1998, is one of the largest population-based Asian cohorts in the world with high-461 quality prospective data on exposure and comprehensive capture of morbidity and mortality. All 462 cancer cases are incident cases diagnosed over three decades of follow-up. This is one of the best 463 resources to evaluate the utility of PRS in a prospective manner. The findings open a window in our 464 current understanding of which PRS is relevant and ready to be deployed in risk-based cancer 465 screening studies.

466

467 Ethnic representation in PRS model development, PRS validation, limited discriminative 468 ability in the general population, ill calibration, insufficient healthcare professional and patient 469 education, and healthcare system integration are all hurdles that must be crossed before PRS can be 470 implemented responsibly as a public health instrument [39, 40]. Importantly, genetic literacy will be a 471 critical prerequisite for the successful implementation of PRS in population-based health screening. It 472 is pivotal that uncertainty associated with risk estimates derived from PRS is communicated clearly 473 [1]. In addition, an individual flagged to be at high risk of developing cancer may be unaware of the 474 range of surveillance options available [41]. In a commentary evaluating the "right not to know" in 475 genomics research by Gold and Green, it was noted that among those who chose not to have their 476 results returned, nearly half of them changed their minds after an education intervention [42].

477

478 While nationwide screening programs have helped to raise cancer awareness, there is still a 479 need to improve the effectiveness and efficiency of cancer screening in Asian countries such as 480 Singapore, given the steadily rising incidence rates. Despite the challenges, a risk-based screening 481 strategy that includes the use of PRS should be actively examined for research and implementation.

482

## 483 **DECLARATIONS**

### 484 **Ethics approval and consent to participate**

485 The study was approved by the institutional review boards of the University of Southern California, the

486 National University of Singapore, and the Agency for Science, Technology and Research (A\*STAR,

487 reference number 2022-042). Written, informed consent was obtained from all study participants.

It is made available under a CC-BY 4.0 International license.



It is made available under a CC-BY 4.0 International license.



- 519 All authors agreed both to be personally accountable for the author's own contributions and to ensure
- 520 that questions related to the accuracy or integrity of any part of the work, even ones in which the
- 521 author was not personally involved, are appropriately investigated, resolved, and the resolution
- 522 documented in the literature.
- 

## **Acknowledgments**

- 525 We thank the Singapore Cancer Registry for the identification of incident cancer cases among
- 526 participants of the Singapore Chinese Health Study and Siew-Hong Low of the National University of
- 527 Singapore for supervising the fieldwork of the Singapore Chinese Health Study.
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 

## 542 **REFERENCES**

543 1. Polygenic Risk Score Task Force of the International Common Disease A: 544 **Responsible use of polygenic risk scores in the clinic: potential benefits, risks**  545 **and gaps**. *Nat Med* 2021, **27**(11):1876-1884. 546 2. Lambert SA, Abraham G, Inouye M: **Towards clinical utility of polygenic risk**  547 **scores**. *Hum Mol Genet* 2019, **28**(R2):R133-R142. 548 3. Clift AK, Dodwell D, Lord S, Petrou S, Brady SM, Collins GS, Hippisley-Cox J: **The**  549 **current status of risk-stratified breast screening**. *Br J Cancer* 2022, **126**(4):533- 550 550. 551 4. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala 552 E, Skytthe A, Hemminki K: **Environmental and heritable factors in the causation**  553 **of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland**. *N*  554 *Engl J Med* 2000, **343**(2):78-85. 555 5. Cano-Gamez E, Trynka G: **From GWAS to Function: Using Functional Genomics**  556 **to Identify the Mechanisms Underlying Complex Diseases**. *Front Genet* 2020, 557 **11**:424. 558 6. Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, Tyrer JP, Chen TH, 559 Wang Q, Bolla MK *et al*: **Polygenic Risk Scores for Prediction of Breast Cancer**  560 **and Breast Cancer Subtypes**. *Am J Hum Genet* 2019, **104**(1):21-34. 561 7. Ho WK, Tan MM, Mavaddat N, Tai MC, Mariapun S, Li J, Ho PJ, Dennis J, Tyrer JP, 562 Bolla MK *et al*: **European polygenic risk score for prediction of breast cancer**  563 **shows similar performance in Asian women**. *Nat Commun* 2020, **11**(1):3833. 564 8. Kachuri L, Graff RE, Smith-Byrne K, Meyers TJ, Rashkin SR, Ziv E, Witte JS, 565 Johansson M: **Pan-cancer analysis demonstrates that integrating polygenic risk**  566 **scores with modifiable risk factors improves risk prediction**. *Nat Commun* 2020, 567 **11**(1):6084. 568 9. Du Z, Gao G, Adedokun B, Ahearn T, Lunetta KL, Zirpoli G, Troester MA, Ruiz-569 Narvaez EA, Haddad SA, PalChoudhury P *et al*: **Evaluating Polygenic Risk Scores**  570 **for Breast Cancer in Women of African Ancestry**. *J Natl Cancer Inst* 2021, 571 **113**(9):1168-1176. 572 10. Jia G, Lu Y, Wen W, Long J, Liu Y, Tao R, Li B, Denny JC, Shu XO, Zheng W: 573 **Evaluating the Utility of Polygenic Risk Scores in Identifying High-Risk**  574 **Individuals for Eight Common Cancers**. *JNCI Cancer Spectr* 2020, **4**(3):pkaa021. 575 11. Lacaze P, Bakshi A, Riaz M, Orchard SG, Tiller J, Neumann JT, Carr PR, Joshi AD, 576 Cao Y, Warner ET *et al*: **Genomic Risk Prediction for Breast Cancer in Older**  577 **Women**. *Cancers (Basel)* 2021, **13**(14). 578 12. Zhang X, Rice M, Tworoger SS, Rosner BA, Eliassen AH, Tamimi RM, Joshi AD, 579 Lindstrom S, Qian J, Colditz GA *et al*: **Addition of a polygenic risk score,**  580 **mammographic density, and endogenous hormones to existing breast cancer**  581 **risk prediction models: A nested case-control study**. *PLoS Med* 2018, 582 **15**(9):e1002644. 583 13. Fritsche LG, Patil S, Beesley LJ, VandeHaar P, Salvatore M, Ma Y, Peng RB, Taliun 584 D, Zhou X, Mukherjee B: **Cancer PRSweb: An Online Repository with Polygenic**  585 **Risk Scores for Major Cancer Traits and Their Evaluation in Two Independent**  586 **Biobanks**. *Am J Hum Genet* 2020, **107**(5):815-836. 587 14. Gafni A, Dite GS, Spaeth Tuff E, Allman R, Hopper JL: **Ability of known colorectal**  588 **cancer susceptibility SNPs to predict colorectal cancer risk: A cohort study**  589 **within the UK Biobank**. *PLoS One* 2021, **16**(9):e0251469. 590 15. Archambault AN, Jeon J, Lin Y, Thomas M, Harrison TA, Bishop DT, Brenner H, 591 Casey G, Chan AT, Chang-Claude J *et al*: **Risk Stratification for Early-Onset**  592 **Colorectal Cancer Using a Combination of Genetic and Environmental Risk**  593 **Scores: An International Multi-Center Study**. *J Natl Cancer Inst* 2022.



It is made available under a CC-BY 4.0 International license.



#### It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) .

674 **Table 1.** Demographics of our study population by gender and cancer site. Demographics variables

were collected using structured questionnaire at recruitment. Family history for lung cancer was not

676 available. Information on cancer occurrence (number of cancer and age at cancer occurrence) was

677 obtained through linkage with the Singapore Cancer Registry in December 2015. Follow-up time was

678 calculated from age at recruitment. IQR: Interquartile range. 679



It is made available under a CC-BY 4.0 International license.





685 **Table 3.** Associations between per standard deviation (SD) increase in site-specific polygenic risk scores and cancer occurrence. Hazard ratios (HR) and

686 corresponding 95% confidence intervals (CI) were estimated using Cox proportional hazard models, adjusted for age at recruitment, dialect group, highest

687 education attained, body mass index, smoking status, alcohol consumption, and physical activity. Follow-up time was censored at 20 years after recruitment.<br>688 Significant results are shown in bold.

Significant results are shown in bold.



690 **Table 4**. Number of individuals estimated to have a hazard ratio (HR) associated with per standard deviation increase in site-specific polygenic risk score 691 above the arbitrary threshold (1.5, 2.0, 2.5 and 3.0). To estimate the HR for each individual, we applied the *predict()* function with option *type="risk"* to the Cox 692 model with PRS (standardised to mean 0 and variance 1) and age at recruitment.





. [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) It is made available under a

It is made available under a CC-BY 4.0 International license

# 694 **Figure 1. Site-specific polygenic risk scores (PRS) performance assessment.**

695 A) Distribution, B) discrimination, C) predictive ability and D) calibration for each of the four common cancers studied. Two-sided, two-sample t-tests with a type I error of 0.05 were used to examine<br>696 whether t

 $\frac{696}{}$  whether there was a difference in the distribution of standardised PRS (subtraction of mean value followed by the division by the standard deviation) between site-specific cancer cases and non-<br> $697$  cancer con

697 cancer controls (A). The PRS showcased are the best-performing scores based on Area Under the Receiver Operator Characteristic Curve (AUC) values in the female and male populations, i)<br>698 unadiusted Isolid linel, and 698 unadjusted [solid line], and ii) adjusted for age at recruitment [dashed line] (B). Each colored line in the plots for predictive ability denotes a five percentile increase in the standardised PRS score in<br>699 (C). Cal

- $699$  (C). Calibration calculated based on five-year absolute risk by PRS deciles in (D). A prediction tool is considered more accurate when the AUC is larger. An AUC of 0.9–1.0 is considered excellent,  $700$  0.8–0.9 verv
- 700 0.8–0.9 very good, 0.7–0.8 good, 0.6–0.7 sufficient, 0.5–0.6 bad, and less than 0.5 considered not useful (PMID: 27683318).

701



. [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/) It is made available under a

It is made available under a CC-BY 4.0 International license

It is made available under a CC-BY 4.0 International license.

# 702 **ADDITIONAL FILES**

703 Additional File 1 - Supplementary tables.xlsx